Carlisle Companies Inc (CSL) News

Carlisle Companies Publishes 2024 Annual Report

Carlisle Companies Incorporated (NYSE:CSL) today published its 2024 Annual Report, highlighting Carlisle’s strategic pivot to a pure play...

Form ARS - Annual Report to Security Holders

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

European Commission Approves CSL and Arcturus Therapeutics’ KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

- KOSTAIVE represents a significant advancement in vaccine technology, demonstrating superior immunogenicity and antibody persistence for up to...

Carlisle Companies Reinforces its Commitment to Innovation Through its New Accelerator

Carlisle Companies Incorporated (NYSE:CSL) is reinforcing its commitment to innovation through the development and execution of its new...